The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes
Carrie R. Wong, Joseph K. Lim – 7 September 2018
Carrie R. Wong, Joseph K. Lim – 7 September 2018
Carla Colombo, Gianfranco Alicandro – 6 September 2018
Sarah E. Kleinstein, Matthew Rein, Manal F. Abdelmalek, Cynthia D. Guy, David B. Goldstein, Anna Mae Diehl, Cynthia A. Moylan – 5 September 2018 – Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease with highly variable outcomes. Patients with simple steatosis typically experience a benign course, whereas those with more advanced liver injury, nonalcoholic steatohepatitis (NASH), and advanced stage fibrosis suffer increased risk for complications such as cirrhosis, hepatic decompensation, and liver cancer.
Carlos J. Pirola, Diego Flichman, Hernán Dopazo, Tomas Fernández Gianotti, Julio San Martino, Cristian Rohr, Martin Garaycoechea, Carla Gazzi, Gustavo O. Castaño, Silvia Sookoian – 5 September 2018 – We report on the presence of a rare nonsense mutation (rs149847328, p.Arg227Ter) in the glucokinase regulator (GCKR) gene in an adult patient with nonalcoholic fatty liver disease (NAFLD), morbid obesity, and type 2 diabetes; this patient developed a progressive histological form of the disease.
The new UNOS organ allocation policy is scheduled to go into effect in December 2018. Work your way through the changes and challenges with the Chair of the AASLD Liver Transplantation SIG and Editor-in-Chief of Liver Transplantation in this first of a series of webinars brought to you by a collaboration of the SIG and journal.Paul Martin (Moderator) Paul Martin MD, FAASLD is Professor of Medicine and Chief of the Divisions of Gastroenterology and Hepatology at the University of Miami, USA.
Anawin Sanguankeo, Sikarin Upala – 4 September 2018
Chhagan Bihari, Deepika Lal, Monika Thakur, Sukriti Sukriti, Dhananjay Mathur, Anupama G. Patil, Lovkesh Anand, Guresh Kumar, Shvetank Sharma, Shalini Thapar, Apurba Rajbongshi, Archana Rastogi, Anupam Kumar, Shiv K. Sarin – 4 September 2018 – Bone loss is common in advanced cirrhosis, although the precise mechanisms underlying bone loss in cirrhosis are unknown. We studied the profile and functionality of bone‐forming cells and bone‐building proteins in bone marrow (BM) of individuals with cirrhosis (n = 61) and individuals without cirrhosis as normal controls (n = 50).
Zobair M. Younossi, Radhika Tampi, Massoom Priyadarshini, Fatema Nader, Issah M. Younossi, Andrei Racila – 4 September 2018 – Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease. Our aim was to estimate the total economic burden of NASH and advanced NASH in the United States. We constructed lifetime Markov models for all stages of NASH and a separate model to specifically identify the increased burden of advanced NASH (fibrosis stage >3). The models comprised patients aged 18+, who moved through seven different health states.
Binita Kamath, Cara Mack – 4 September 2018
Jingwen Wang, Jianwen Chen, Yang Liu, Xianhuang Zeng, Mingcong Wei, Shaoshuai Wu, Qiushuang Xiong, Feifei Song, Xu Yuan, Yu Xiao, Yun Cao, Changyong Li, Lang Chen, Mingxiong Guo, Yun‐Bo Shi, Guihong Sun, Deyin Guo – 4 September 2018 – Hepatitis B virus (HBV) is a major risk factor for the development and progression of hepatocellular carcinoma. It has been reported that viral infection can interfere with cellular microRNA (miRNA) expression and participate in the pathogenesis of oncogenicity.